Torsten Haferlach

Research interests

Publications

• Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

  Blood · 2022 · https://doi.org/10.1182/blood.2022015853

• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

  Leukemia · 2022 · https://doi.org/10.1038/s41375-022-01613-1

• Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

  Blood · 2022 · https://doi.org/10.1182/blood.2022018221

• Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.01659

• Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms

  Blood · 2020 · https://doi.org/10.1182/blood.2019004229

• SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

  Blood · 2020 · https://doi.org/10.1182/blood.2020004850

• TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

  Leukemia · 2019 · https://doi.org/10.1038/s41375-018-0351-2

• Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

  Blood · 2018 · https://doi.org/10.1182/blood-2017-09-801498

• Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation

  Blood · 2017 · https://doi.org/10.1182/blood-2016-12-754796

• Dynamics of clonal evolution in myelodysplastic syndromes

  Nature Genetics · 2016 · https://doi.org/10.1038/ng.3742

• Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

  Cancer Discovery · 2013 · https://doi.org/10.1158/2159-8290.cd-13-0609

• Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.47.3314

• Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

  Leukemia · 2013 · https://doi.org/10.1038/leu.2013.336

• BRAF Mutations in Hairy-Cell Leukemia

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1014209

• Frequent pathway mutations of splicing machinery in myelodysplasia

  Nature · 2011 · https://doi.org/10.1038/nature10496

• Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.30.2554

• Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

  The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(10)62105-8

• Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2007.15.4245

• Global approach to the diagnosis of leukemia using gene expression profiling

  Blood · 2005 · https://doi.org/10.1182/blood-2004-12-4938

• KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

  Blood · 2005 · https://doi.org/10.1182/blood-2005-04-1466

• Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

  Blood · 2005 · https://doi.org/10.1182/blood-2005-06-2248

• Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

  Blood · 2004 · https://doi.org/10.1182/blood-2004-03-1036

• Morphologic Dysplasia in De Novo Acute Myeloid Leukemia (AML) Is Related to Unfavorable Cytogenetics but Has No Independent Prognostic Relevance Under the Conditions of Intensive Induction Therapy: Results of a Multiparameter Analysis From the German AML Cooperative Group Studies

  Journal of Clinical Oncology · 2003 · https://doi.org/10.1200/jco.2003.08.005

• AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases

  Blood · 2003 · https://doi.org/10.1182/blood-2003-02-0434

• Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML

  Leukemia · 2003 · https://doi.org/10.1038/sj.leu.2403187

• New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts

  Blood · 2003 · https://doi.org/10.1182/blood-2003-03-0880

• Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

  Blood · 2002 · https://doi.org/10.1182/blood-2002-02-0532

• Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

  Blood · 2002 · https://doi.org/10.1182/blood.v100.1.59

• Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases

  Leukemia · 2002 · https://doi.org/10.1038/sj.leu.2402329

• AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia

  Nature Medicine · 2001 · https://doi.org/10.1038/86515

• Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML

  Leukemia · 2000 · https://doi.org/10.1038/sj.leu.2401773

• Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.

  PubMed · 1999 · https://doi.org/10.1182/blood.v93.12.4116

Current projects

No projects listed.